Dr. Reddy's Laboratories Balance Sheet Health

Financial Health criteria checks 6/6

Dr. Reddy's Laboratories has a total shareholder equity of ₹267.9B and total debt of ₹16.1B, which brings its debt-to-equity ratio to 6%. Its total assets and total liabilities are ₹372.8B and ₹105.0B respectively. Dr. Reddy's Laboratories's EBIT is ₹67.5B making its interest coverage ratio -106.7. It has cash and short-term investments of ₹72.6B.

Key information

6.0%

Debt to equity ratio

₹16.14b

Debt

Interest coverage ratio	-106.7x
Cash	₹72.55b
Equity	₹267.85b
Total liabilities	₹104.99b
Total assets	₹372.84b

Recent financial health updates

No updates

Recent updates

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Nov 29

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Jan 20

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Nov 07

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Jul 28

Dr. Reddy's launches generic drugs for allergies in US

Jul 22

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul 05

Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine in India

May 31

Financial Position Analysis

Short Term Liabilities: RDY's short term assets (₹238.5B) exceed its short term liabilities (₹93.6B).

Long Term Liabilities: RDY's short term assets (₹238.5B) exceed its long term liabilities (₹11.4B).

Debt to Equity History and Analysis

Debt Level: RDY has more cash than its total debt.

Reducing Debt: RDY's debt to equity ratio has reduced from 31.8% to 6% over the past 5 years.

Debt Coverage: RDY's debt is well covered by operating cash flow (332%).

Interest Coverage: RDY earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dr. Reddy's Laboratories Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Recent updates

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's: Growth Supported By New Labels, Profitability

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's launches generic drugs for allergies in US

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2022

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jun 29, 2022

Dr. Reddy's Laboratories Limited Launches Posaconazole Delayed-Release Tablets in the U.S. Market

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Dr. Reddy's Laboratories Limited Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Alium JSC entered into agreement to acquire Two anti-bacterial brand Ciprolet and Levolet from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT Vials in the U.S. Market

Dr. Reddy's Laboratories Limited Announces DCGI Approval to the Single-Shot Sputnik Light Vaccine in India

Dr. Reddy's Laboratories Limited (BSE:500124) agreed to acquire Nimbus Health GmbH.

Dr. Reddy's Laboratories Limited Appoints Penny Wan as an Additional Director

Dr. Reddy's Laboratories Limited Receives DCGI Approval to Launch Molnupiravir Capsules 200Mg (Molflu™) in India

Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

Dr. Reddy's Launches Hair Loss Treatment Drug for Women

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.